Bellicum Pharmaceuticals Inc.:
Molecular switch technology and co-stim domains enables pharmacologic control over cells for enhanced efficacy and safety. Lead (registrational EU) program: Ph2 for rivo-cel (alpha/beta addback T-cell therapy for post allogeneic HSTC in non-malignant and malignant diseases). Positive late interim analysis on rivo-cel exp at ASH 2018; full dataset (N=234) exp H1 19. BPX-601: GoCAR-T featuring iMC (inducible MyD88/CD40) activation switch targeting PSCA expressing solid tumors; BPX-701: TCR targeting PRAME.
US - West South Central
Phase l or ll
Immuno-Oncology, Oncology, Rare Disease
2130 West Holcombe Boulevard, Suite 800
Texas Life Science Plaza
Houston, TX 77030
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Top 10 Holders of Bellicum Pharmaceuticals Inc
Top 10 Holders of BELLICUM PHARMACEUTICALS PFD SR 1
Ownership data is sourced through FactSet.
Stock Market Data
Market Data copyright © 2020 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by